1Cancer Statistics Center 2019 Estimates. American Cancer Society; 2018. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Ovary.

2Lee P, Rosen DG, Zhu C, Silva EG, Liu J. (2005) Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecologic oncology. 3:671-677.

3Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, et.al. (1998) Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. Journal of experimental & clinical cancer research: CR. 2:231-237.

4Hatch KD, Beecham JB, Blessing JA, Creasman WT. (1991) Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 2:269-271.

5Markman M, Webster K, Zanotti K, Rohl J, Belinson J. (2004) Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecologic oncology. 2:390-393.

6Van Der Velden J, Gitsch G, Wain GV, Friedlander ML, Hacker NF. (1995) Tamoxifen in patients with advanced epithelial ovarian cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 4:301-305.

7Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, et al. (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology. 2:112-117.

8Chadha S, Rao BR, Slotman BJ, van Vroonhoven CC, van der Kwast TH. (1993) An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. Human pathology. 1:90-95.

9Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, et al. (2010) Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. Journal of ovarian research. 3:14.

10Zhang ZJ, Li S. (2014) The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes, obesity & metabolism. 8:707-710.

11Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. 5:575-586.

12Bolton EC, So AY, Chaivorapol C, Haqq CM, Li H, Yamamoto KR. (2007) Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 16:2005- 2017.

13Pal SK, He M, Tong T, Wu H, Liu X, Lau C, et al. (2015) RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. Molecular cancer research: MCR. 1:130-137.

14Cancer Genome Atlas Research N. (2015) The Molecular Taxonomy of Primary Prostate Cancer. Cell 4:1011-1025.

15Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, et al. (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 4:321-330.

16Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, et al. (2002) The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A. 18:11890-11895.

17Walters KA, Allan CM, Handelsman DJ (2008) Androgen actions and the ovary. Biol Reprod.78:380-389.

18Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, et al. (1983) Characterization of a human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and estrogen receptors. Cancer Res. 11:5379-5389.

19Estep AL, Palmer C, McCormick F, Rauen KA. (2007) Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PloS one. 12: e1279.

20Slomovitz BM, Coleman RL (2012) The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 21:5856-5864.

21Aggarwal R, Zhang T, Small EJ, Armstrong AJ. (2014) Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. Journal of the National Comprehensive Cancer Network: JNCCN. 5:719-726.

22Tiffany Traine DYea.(2015) Results from a phase 2 study of enzalutamide and AR inhibition in advanced AR positive triple negative breast cancer. ASCO 2015.

23Luo J, Jin J, Yang F, Sun Z, Zhang W, Shi Y, et al. (2016) The Correlation Between PARP1 and BRCA1 in AR Positive Triple- negative Breast Cancer. International journal of biological sciences. 12:1500-1510.

24Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, et al. (2015) Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. American journal of obstetrics and gynecology. 4:479 e471- 479 e410.

25Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, et al. (2012) Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstetrics and gynecology. 1:61-67.

26Garrett CR, Hassabo HM, Bhadkamkar NA, Wen S, Baladandayuthapani V, Kee BK, et al. (2012) Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. British journal of cancer. 8:1374-1378.

27Lee S, Choi EJ, Jin C, Kim DH. (2005) Activation of PI3K/ Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecologic oncology. 1:26-34.